Immunostimulatory monoclonal antibodies for cancer therapy

440Citations
Citations of this article
362Readers
Mendeley users who have this article in their library.

This artice is free to access.

Abstract

Increasing immune responses with immunostimulatory monoclonal antibodies (mAbs) directed to immune-receptor molecules is a new and exciting strategy in cancer therapy. This expanding class of agents functions on crucial receptors, either antagonizing those that suppress immune responses or activating others that amplify immune responses. Complications such as autoimmunity and systemic inflammation are problematic side effects associated with these agents. However, promising synergy has been observed in preclinical models using combinations of immunostimulatory antibodies and other immunotherapy strategies or conventional cancer therapies. Importantly, mAbs of this type have now entered clinical trials with encouraging initial results. © 2007 Nature Publishing Group.

Cite

CITATION STYLE

APA

Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007, February). Immunostimulatory monoclonal antibodies for cancer therapy. Nature Reviews Cancer. https://doi.org/10.1038/nrc2051

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free